Mouse antibody for Alzheimer’s
.
Alzheimer's Donation
Donate Online Now
.

Stockholm’s Bioarctic Neuroscience has signed an agreement with MRC Technology in London to humanize a mouse antibody under development at Bioarctic for the treatment of Alzheimer’s disease.
MRC Technology’s therapeutic antibody group will use its proprietary humanization technology to generate the humanized clinical candidate.

Bioarctic will pay the London company an upfront fee, development milestones and royalties.

In return, Bioarctic will retain all development and commercialization rights to the antibody. The financial value of the deal was not disclosed.

Bioarctic’s antibody is being developed together with Eisai Japan, a company that developed and markets the drug Aricept for Alzheimer’s disease.

“BioArctic has developed a unique amyloid beta conformational specific antibody (LSAP) for the treatment of Alzheimer’s disease. This antibody targets a newly discovered toxic form of amyloid beta protein called protofibrils that initiates and drives the disease. The antibody will provide an opportunity for early treatment of the disease of significant advantage to the patient,” said Pär Gellerfors, CEO of BioArctic.